Related Experiment Video
Updated: Feb 22, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.4K
[Pitavastatin and new diabetes development]
1Department of Endocrinology and Metabolic Diseases, Florence Nightingale Hospital, İstanbul, Turkey. kubilayukinc@me.com.
Summary
Statins manage cardiovascular disease but can increase type 2 diabetes risk. Pitavastatin, a statin, shows potential benefits for glucose metabolism and renal function, unlike some other statins.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Dyslipidemia management is crucial for cardiovascular disease (CVD) prevention.
- Statins are primary agents for CVD prevention, including in type 2 diabetes mellitus (T2DM) patients.
- Statin use can paradoxically increase T2DM risk, with varying effects on glucose metabolism among different statins.
Purpose of the Study:
- To evaluate the role of pitavastatin in managing dyslipidemia and its potential impact on glucose metabolism and renal function.
- To compare the glucose-raising or diabetogenic capacity of pitavastatin with other statins.
Main Methods:
- Review of existing literature on statin therapy, dyslipidemia, T2DM, and pitavastatin.
- Analysis of pitavastatin's pharmacological profile and reported pleiotropic effects.
- Comparison of glucose metabolism and renal function outcomes associated with pitavastatin versus other statins.
Main Results:
- Pitavastatin, a newer statin, possesses pleiotropic effects beneficial for cardiovascular health.
- These effects include reducing inflammation, lipid oxidation, and improving endothelial function.
- Pitavastatin may improve glucose metabolism and renal function, potentially mitigating risks associated with other statins.
Conclusions:
- Pitavastatin represents a potentially favorable option in managing dyslipidemia, especially in patients at risk for or with T2DM.
- Its pleiotropic actions may offer cardiovascular benefits beyond lipid-lowering, with a potentially neutral or beneficial effect on glucose metabolism and renal function.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
759
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
759
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
712
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
712
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:06Oral Hypoglycemic Agents: Glinides
733
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
733
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K